Homology Medicines

Homology Medicines, Inc. is a genetic medicines company focused on rare genetic diseases, addressing their underlying genetic cause rather than symptoms. Its platform is built on a family of 15 human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), naturally occurring AAVs isolated from human CD34+ cells, which it uses to deliver genetic medicines in vivo through either conventional gene therapy or a nuclease-free gene-editing modality. The editing approach, branded AMEnDR (AAV-Mediated Editing by Directed Homologous Recombination), relies on homologous recombination to correct disease mutations or insert therapeutic sequences using a single AAV vector without exogenous nucleases or promoters. The company also described a GTx-mAb platform intended to deliver one-time gene therapy that produces antibodies systemically.

The clinical and preclinical pipeline centered on phenylketonuria (PKU): HMI-102, a gene therapy for adults with PKU that entered a Phase 2 trial called pheNIX, and HMI-103, a gene-editing candidate for PKU in pediatric patients. Other programs included HMI-203 for Hunter syndrome / mucopolysaccharidosis type II, HMI-202 for metachromatic leukodystrophy and HMI-104 for paroxysmal nocturnal hemoglobinuria. Registered clinical trials sponsored by the company include NCT04768348 and NCT05222178 in PKU and NCT05238324 in MPS II. The breadth of AAVHSC serotypes was said to allow targeting of liver, central and peripheral nervous system, bone marrow, cardiac and skeletal muscle and eye through a single injection.

In July 2023 Homology halted research and reduced its workforce by 87% while pursuing strategic alternatives, after early PKU gene-editing data showed mixed phenylalanine reductions across three dosed patients.

Founding story

Sources give conflicting accounts of the founders. BioSpace reports that Homology was founded and incubated with a seed investment inside the 4:59 Initiative, the company creation engine of 5AM Ventures, with co-founders Saswati Chatterjee of the Beckman Research Institute at City of Hope and Laura Smith, a postdoctoral fellow in the AAV Lab and Department of Surgery; the company holds an exclusive worldwide license to the technology platform based on Chatterjee's research, whose team led the first AAV vector-mediated gene transfer studies into human hematopoietic stem cells and isolated naturally occurring AAVs from human CD34+ cells. A separate wiki entry instead names Dr. Fritz French and Dr. John Travers as 2015 founders. The management team recruited at launch was drawn largely from Shire Pharmaceuticals' rare disease organization, including CEO Arthur Tzianabos, COO Sam Rasty and CSO Albert Seymour.

Business model

Homology developed proprietary genetic medicines in-house, building foundational intellectual property around human-derived AAV vectors and licensing in complementary technology (an exclusive worldwide license to the City of Hope/Chatterjee platform and a Caltech AAV capsid license). Its programs were pre-commercial, funded by venture financing and, after 2018, public equity markets, and it listed Oxford Biomedica as a partner. Following the 2023 restructuring, the company halted research and pursued a sale, merger or other business combination.

No product revenue is described in the sources; funding came from venture rounds, a 2018 IPO and later financings. One aggregator lists estimated revenue of $2M-$5M and another estimates $15M-$40M, figures that are unverified aggregator estimates.

Traction

Homology moved from preclinical IND-enabling work in 2017 to clinical-stage status, sponsoring trials in PKU (NCT04768348, NCT05222178) and MPS II (NCT05238324), with HMI-102 reaching a Phase 2 trial (pheNIX). Headcount rose from 12 at launch in 2016 to 40 in 2017 and 92 full-time employees at the end of 2022. Cumulative disclosed funding reached $127 million by the 2017 Series B, followed by a $144 million IPO in 2018 and a reported $60 million financing in 2020. In July 2023 the company reported initial three-patient gene-editing data and then halted research.

Latest developments

In July 2023 Homology reported initial data from three patients dosed with its nuclease-free gene-editing PKU candidate, showing phenylalanine reductions in two of three patients, variability in the second and an increase in the third, with no serious safety events and normal liver function tests under preventive immunosuppression. Citing the financing environment and long development timelines, it simultaneously announced an 87% workforce reduction, a halt to research and a review of strategic options including an acquisition or asset sale, with roughly $150 million in cash as of 31 March 2023 funding operations into 2026. A startup directory subsequently listed the company as acquired by Q32 Bio.